Following the EMA's recommendation back in February, the European Commission has now approved Sanofi Pasteur's 6-in-1 paediatric vaccine Hexyon/Hexacima (DTaP-IPV-HiB-HepB) for primary and booster vaccination of infants from six weeks of age.
The vaccine will be sold as Hexyon in Western Europe as a joint venture between Sanofi Pasteur and MSD. In Eastern Europe, however, the vaccine will be called Hexacima and will be marketed only by Sanofi Pasteur. It will be the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against:
- Hepatitis B
- Haemophilus influenza B
Hexyon/Hexacima will be looking to compete with GlaxoSmithKline's (GSK) hexavalent vaccine Infanrix Hexa. Infanrix has been the only hexavalent paediatric vaccine available in the European market since 2005, following the removal of Sanofi Pasteur MSD's Hexavac vaccine from the market.
Do you think the fully-liquid nature of the vaccine will be enough to overthrow GSK's current dominance in the hexavalent market?
You can join our discussion on LinkedIn or leave a comment below, I'd love to hear what you think. You might be interested in attending the World Vaccine Congress Europe 2013, 16-17 October, Lille, France.